Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: valproate Clear all
Terminated Phase 1 Interventional

Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

NCT01007695
View directory record Official record
Conditions
Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

NCT00530907
View directory record Official record
Conditions
Advanced Cancer
Interventions
Valproic Acid, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Azacytidine and Valproic Acid in Patients With Advanced Cancers

NCT00496444
View directory record Official record
Conditions
Advanced Cancers
Interventions
Azacitidine, Valproic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686
View directory record Official record
Conditions
Bipolar I Disorder, Alcohol Dependence
Interventions
Quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

NCT00402324
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
olanzapine, placebo, divalproex
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Treatment and Outcome of Early Onset Bipolar Disorder

NCT00048802
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

NCT00177567
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium carbonate, Depakote-ER, risperidone, olanzapine, paroxetine, bupropion, lamotrigine, venlafaxine, tranylcypromine, mirtazapine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

NCT00308360
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, divalproex
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

NCT00996060
View directory record Official record
Conditions
Lung Cancer
Interventions
Hydralazine and Valproic Acid: Cohort 1, Hydralazine and Valproic Acid: Cohort 0, Hydralazine and Valproic Acid: Cohort 2, Hydralazine and Valproic Acid: Cohort 3, Hydralazine and Valproic Acid: Cohort 4, Hydralazine and Valproic Acid: Cohort 5
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 25, 2026, 6:34 AM EDT
Withdrawn Phase 4 Interventional

Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder

NCT01075126
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Depakote, Lithium
Drug
Lead sponsor
Lawson, William B., M.D., PhD, DFAPA
Individual
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional

Drug Treatment for Alcoholics With Bipolar Disorder

NCT00000439
View directory record Official record
Conditions
Alcoholism, Bipolar Disorder
Interventions
sodium valproate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER

NCT00211250
View directory record Official record
Conditions
Mood Disorder
Interventions
Valproic Acid and Depakote ER
Drug
Lead sponsor
Joliet Center for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

NCT00879437
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

NCT01106872
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma, Metastatic Sarcoma
Interventions
Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 25, 2026, 6:34 AM EDT
Withdrawn Phase 2 Interventional

Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

NCT00204503
View directory record Official record
Conditions
Bipolar I or II Depression and Alcohol Abuse or Dependence
Interventions
Depakote ER
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 25, 2026, 6:34 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Anti-epileptic Drugs in Obese Children

NCT02993861
View directory record Official record
Conditions
Epilepsy, Obese
Interventions
Anti-epileptics
Other
Lead sponsor
Christoph P Hornik, MD MPH
Other
Eligibility
2 Years to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings

NCT02078596
View directory record Official record
Conditions
Irritable Aggression
Interventions
Divalproex
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
7 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 25, 2026, 6:34 AM EDT
Not listed Phase 4 Interventional

Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote

NCT00312676
View directory record Official record
Conditions
Epilepsy, Behavioral Disturbance
Interventions
Rapid versus slow conversion
Procedure
Lead sponsor
Veterans Affairs Medical Center, Miami
Federal
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2006 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

NCT00312494
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 25, 2026, 6:34 AM EDT
Not listed Phase 1 Interventional

A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

NCT01898676
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
Drug
Lead sponsor
Vince & Associates Clinical Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 25, 2026, 6:34 AM EDT
Withdrawn Phase 2 Interventional

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

NCT01011998
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Gleevec (imatinib), valproic acid
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism

NCT00211757
View directory record Official record
Conditions
Autism
Interventions
Divalproex sodium, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 25, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT00404248
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 25, 2026, 6:34 AM EDT